FH535 inhibits the proliferation of HepG2 cells via downregulation of the Wnt/β‑catenin signaling pathway

Liu,Jing; Li,Guangbing; Liu,Dejie; Liu,Jun

doi:10.3892/mmr.2014.1928

FH535 inhibits the proliferation of HepG2 cells via downregulation of the Wnt/β‑catenin signaling pathway

Authors:
- Jing Liu
- Guangbing Li
- Dejie Liu
- Jun Liu
View Affiliations

Affiliations: Department of Ophthalmology, The Second Hospital of Shandong University, Jinan, Shandong 250033, P.R. China, Department of Liver Transplantation and Hepatobiliary Surgery, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China, Department of Anesthesiology, Qilu Hospital Affiliated to Shandong University, Jinan, Shandong 250012, P.R. China
Published online on: January 30, 2014 https://doi.org/10.3892/mmr.2014.1928
Pages: 1289-1292

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC) is a primary cancer of the liver. Target therapy may improve prognosis of HCC. In the present study, we evaluated the inhibition of the Wnt/β‑catenin pathway as a potential therapeutic approach. HepG2 cells were treated with the β‑catenin inhibitor FH535. β‑catenin protein expression was semi‑quantitatively assessed using western blot analysis. Cell proliferation was examined with a 3‑(4,5‑dimethyl‑2‑yl)‑5‑(3‑carboxymethoxyphenyl)‑2‑(4‑sulfophenyl)‑2H‑tetrazolium salt (MTS) assay. The mRNA expression of nitric oxide synthase (iNOS) was detected by reverse transcription polymerase chain reaction. The Griess assay was used to determine nitric oxide (NO) concentration. FH535 inhibited the proliferation of HepG2 cells and decreased β‑catenin protein expression. mRNA expression of iNOS, a target gene of the Wnt/β‑catenin pathway, was decreased in FH535‑treated HepG2 cells compared to the control group. NO production was also reduced by FH535. In conclusion, the β‑catenin inhibitor FH535 may inhibit HCC cell proliferation via downregulation of the Wnt/β‑catenin pathway. Thus, targeting this pathway may be useful in HCC therapy.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
2	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
3	Yang Z, Miao R, Li G, Wu Y, Robson SC, Yang X, Zhao Y, Zhao H and Zhong Y: Identification of recurrence related microRNAs in hepatocellular carcinoma after surgical resection. Int J Mol Sci. 14:1105–1118. 2013. View Article : Google Scholar : PubMed/NCBI
4	Bruix J and Sherman M: Management of hepatocellular carcinoma: an update. Hepatology. 53:1020–1022. 2011. View Article : Google Scholar : PubMed/NCBI
5	Wertheim JA, Petrowsky H, Saab S, Kupiec-Weglinski JW and Busuttil RW: Major challenges limiting liver transplantation in the United States. Am J Transplant. 11:1773–1784. 2011. View Article : Google Scholar : PubMed/NCBI
6	El-Serag HB, Marrero JA, Rudolph L and Reddy KR: Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 134:1752–1763. 2008. View Article : Google Scholar : PubMed/NCBI
7	Yeh JJ and Uemura M: Hepatocellular carcinoma. N Engl J Med. 366:92author reply 92–93. 2012. View Article : Google Scholar : PubMed/NCBI
8	MacDonald BT, Tamai K and He X: Wnt/β-catenin signaling: components, mechanisms, and diseases. Dev Cell. 17:9–26. 2009.
9	Thompson MD and Monga SP: WNT/β-catenin signaling in liver health and disease. Hepatology. 45:1298–1305. 2007.
10	Clevers H: Wnt/β-catenin signaling in development and disease. Cell. 127:469–480. 2006.
11	Burke ZD and Tosh D: The Wnt/β-catenin pathway: master regulator of liver zonation? Bioessays. 28:1072–1077. 2006.
12	Siuta M, Zuckerman SL and Mocco J: Nitric oxide in cerebral vasospasm: theories, measurement, and treatment. Neurol Res Int. 2013:9724172013. View Article : Google Scholar : PubMed/NCBI
13	Ozel RE, Alkasir RS, Ray K, Wallace KN and Andreescu S: Comparative evaluation of intestinal nitric oxide in embryonic zebrafish exposed to metal oxide nanoparticles. Small. 9:4250–4261. 2013. View Article : Google Scholar : PubMed/NCBI
14	Du Q, Zhang X, Cardinal J, Cao Z, Guo Z, Shao L and Geller DA: Wnt/beta-catenin signaling regulates cytokine-induced human inducible nitric oxide synthase expression by inhibiting nuclear factor-kappaB activation in cancer cells. Cancer Res. 69:3764–3771. 2009. View Article : Google Scholar
15	Bosch FX, Ribes J, Diaz M and Cléries R: Primary liver cancer: worldwide incidence and trends. Gastroenterology. 127(Suppl 1): S5–S16. 2004. View Article : Google Scholar : PubMed/NCBI
16	Hora C, Romanque P and Dufour JF: Effect of sorafenib on murine liver regeneration. Hepatology. 53:577–586. 2011. View Article : Google Scholar : PubMed/NCBI
17	Pitot HC: Adventures in hepatocarcinogenesis. Annu Rev Pathol. 2:1–29. 2007. View Article : Google Scholar : PubMed/NCBI
18	Hussain SP, Schwank J, Staib F, Wang XW and Harris CC: TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene. 26:2166–2176. 2007. View Article : Google Scholar : PubMed/NCBI
19	Willert K and Jones KA: Wnt signaling: is the party in the nucleus? Genes Dev. 20:1394–1404. 2006. View Article : Google Scholar : PubMed/NCBI
20	Gordon MD and Nusse R: Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem. 281:22429–22433. 2006. View Article : Google Scholar : PubMed/NCBI
21	Thu KL, Radulovich N, Becker-Santos DD, Pikor LA, Pusic A, Lockwood WW, Lam WL and Tsao MS: SOX15 is a candidate tumor suppressor in pancreatic cancer with a potential role in Wnt/β-catenin signaling. Oncogene. Jan 14–2013.(Epub ahead of print). View Article : Google Scholar
22	Clements WM, Wang J, Sarnaik A, Kim OJ, MacDonald J, Fenoglio-Preiser C, Groden J and Lowy AM: β-Catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer. Cancer Res. 62:3503–3506. 2002.
23	Li H, Mo J, Jia G, Liu C, Luan Z and Guan Y: Activation of Wnt signaling inhibits the pro-apoptotic role of Notch in gastric cancer cells. Mol Med Rep. 7:1751–1756. 2013.PubMed/NCBI
24	Shapiro M, Akiri G, Chin C, Wisnivesky JP, Beasley MB, Weiser TS, Swanson SJ and Aaronson SA: Wnt pathway activation predicts increased risk of tumor recurrence in patients with stage I nonsmall cell lung cancer. Ann Surg. 257:548–554. 2013. View Article : Google Scholar : PubMed/NCBI
25	Lustig B and Behrens J: The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol. 129:199–221. 2003.PubMed/NCBI
26	Luo X, Li HX, Liu RX, Wu ZS, Yang YJ and Yang GS: β-catenin protein utilized by Tumour necrosis factor-alpha in porcine preadipocytes to suppress differentiation. BMB Rep. 42:338–343. 2009.